MEDIA RELEASE PR35234
Osaka City University Hospital Treats First Prostate Cancer Patients With Elekta VMAT
OSAKA, July 3 /PRNewswire-AsiaNet/ --
Osaka City University Hospital (Osaka, Japan) has implemented an
innovative cancer treatment from Elekta called Volumetric Modulated Arc
Therapy (VMAT). Using a combination of Elekta Synergy and ERGO++ treatment
planning, VMAT can significantly shorten treatment times and provides
precise, organ-sparing radiation therapy.
The first VMAT treatment at Osaka City University Hospital took place on
March 9. It was a fractional dose of 2 Gy, delivered to a patient with
prostate cancer, and the delivery time was just 110 seconds.
Assistant Professor Kentaro Ishii, M.D., Ph.D., said, "A simple inverse
plan, with dose constraints to the target and several organs at risk,
resulted in a dose distribution comparable to IMRT. The delivery time of less
than two minutes was just amazing."
VMAT with Elekta Synergy and ERGO++ treatment planning system provides
simultaneous control of gantry position and speed, multileaf collimator (MLC)
leaves, dose rate and collimator angle, while the beam is on and rotating.
ERGO++ uses a special algorithm to perform split-second dose calculations,
enabling highly conformal and complex plans, while ensuring the maximum
possible dose is delivered to the target.
Osaka City University Hospital is the second facility in Japan to begin
VMAT treatments. Since the first patient was treated in March, two additional
prostate patients have been treated with VMAT. Plans are now being made to
begin treating brain tumors, as well as head and neck tumors.
"In Japan, the number of cancer patients has been dramatically
increasing, leading to problematically high demands on radiotherapy
facilities," says Dr. Ishii. "VMAT is our quantum-leap solution to provide
high precision treatment to the quickly increasing cancer population."
About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning systems
for radiation therapy and radiosurgery, as well as workflow enhancing
software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to both
healthcare providers and patients, Elekta aims to improve, prolong and even
save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients receive
diagnosis, treatment or follow-up with the help of a solution from the Elekta
Group.
Elekta employs around 2,500 employees globally. The corporate headquarter
is located in Stockholm, Sweden, and the company is listed on the Nordic
Exchange under the ticker EKTAb. For more information about Elekta, please
SOURCE: Elekta
CONTACT: Stina Thorman
Investor Relations
Elekta AB
+46 8 587 254 37
+46 70 778 60 10
stina.thorman@elekta.com;
or
Eri Takayanagi
Elekta KK
+81 3 6722 3800
eri.takayanagi@elekta.com
Translations:
NEWS 
